Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12613000582752
Ethics application status
Approved
Date submitted
22/05/2013
Date registered
24/05/2013
Date last updated
20/11/2019
Date data sharing statement initially provided
20/11/2019
Date results information initially provided
20/11/2019
Type of registration
Prospectively registered
Titles & IDs
Public title
Effect of adjunct high-dose vitamin D on community-acquired pneumonia in hospitalised adults - a randomised controlled trial
Query!
Scientific title
Effect of adjunct high-dose vitamin D on radiographic and clinical outcomes of community-acquired pneumonia in hospitalised adults - a double-blind, placebo-controlled, randomised controlled trial
Query!
Secondary ID [1]
282549
0
Nil
Query!
Universal Trial Number (UTN)
U1111-1140-2885
Query!
Trial acronym
VIDCAPS
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pneumonia
289218
0
Query!
Condition category
Condition code
Infection
289553
289553
0
0
Query!
Other infectious diseases
Query!
Respiratory
289554
289554
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Vitamin D3, 200,000 IU as a single dose orally.
Administration will be directly observed.
Query!
Intervention code [1]
287217
0
Treatment: Drugs
Query!
Comparator / control treatment
Placebo, identical in appearance to the treatment, administered as a single oral dose.
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
289643
0
The resolution of pulmonary inflammatory infiltrate on a follow-up chest X-ray.
Query!
Assessment method [1]
289643
0
Query!
Timepoint [1]
289643
0
6 weeks after taking study treatment.
Query!
Secondary outcome [1]
302928
0
Length of hospital stay.
Query!
Assessment method [1]
302928
0
Query!
Timepoint [1]
302928
0
At discharge from index hospital admission
Query!
Secondary outcome [2]
302929
0
In-hospital mortality.
Query!
Assessment method [2]
302929
0
Query!
Timepoint [2]
302929
0
At death or discharge from hospital.
Query!
Secondary outcome [3]
302930
0
Intensive care unit admission.
Query!
Assessment method [3]
302930
0
Query!
Timepoint [3]
302930
0
During index hospital admission.
Query!
Secondary outcome [4]
302931
0
Amount and duration of antimicrobial therapy.
Query!
Assessment method [4]
302931
0
Query!
Timepoint [4]
302931
0
During index hospitalisation.
Query!
Secondary outcome [5]
302932
0
Readmission to hospital.
Query!
Assessment method [5]
302932
0
Query!
Timepoint [5]
302932
0
After index hospitalisation until 6 week follow-up.
Query!
Secondary outcome [6]
302933
0
6-week and 12-month mortality.
Query!
Assessment method [6]
302933
0
Query!
Timepoint [6]
302933
0
6 weeks and 12 months after treatment/placebo administration..
Query!
Secondary outcome [7]
302934
0
Resolution of symptoms as assessed by questionnaire designed specifically for this study.
Query!
Assessment method [7]
302934
0
Query!
Timepoint [7]
302934
0
6 weeks after treatment/placebo administration.
Query!
Secondary outcome [8]
302935
0
Return to normal activity as assessed by questionnaire designed specifically for this study.
Query!
Assessment method [8]
302935
0
Query!
Timepoint [8]
302935
0
6 weeks after treatment/placebo administration.
Query!
Eligibility
Key inclusion criteria
(1) A confirmed radiological diagnosis of pneumonia, defined as: ‘New inflammatory infiltrate on a chest radiograph where patients have an acute illness with clinical features of pneumonia and radiographic pulmonary shadowing that is at least segmental or present in one lobe and is neither pre-existing or because of some other known cause.’
(2) <48 hours since admission to hospital
(3) Age >=18 years
(4) Ability to give informed consent
(5) Ability to orally consume the study medication
(6) Ability to attend a follow-up appointment at 6 weeks post-study treatment for a chest x-ray
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
(1) Pneumonia is not the principal reason for admission
(2) Pneumonia associated with bronchial obstruction, bronchiectasis, or known tuberculosis
(3) Use of vitamin D3 supplements other than as part of a multivitamin preparation where the daily intake would not exceed 400 IU.
(4) High plasma corrected calcium > 2.6 mmol/L (corrected for plasma albumin concentration)
(5) Use of immunosuppressants (e.g. doses of prednisone >10mg, methotrexate, azathioprine and cyclosporin)
(6) Any prior history of hypercalcaemia, nephrolithiasis or sarcoidosis
(7) Current kidney disorders requiring dialysis treatment or polycystic kidney disease
(8) Cirrhosis of the liver
(9) Already enrolled or planning to enrol in a research study that would conflict with full participation in the study or confound the observation or interpretation of the study findings (e.g. where vitamin D levels are tested and results are known by the participant; where the participant is required to take conflicting medications)
(10) Pregnancy or breast-feeding.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Data analysis is complete
Query!
Reason for early stopping/withdrawal
Participant recruitment difficulties
Query!
Date of first participant enrolment
Anticipated
24/06/2013
Query!
Actual
27/06/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
3/12/2015
Query!
Date of last data collection
Anticipated
Query!
Actual
5/12/2016
Query!
Sample size
Target
400
Query!
Accrual to date
Query!
Final
135
Query!
Recruitment outside Australia
Country [1]
5096
0
New Zealand
Query!
State/province [1]
5096
0
Query!
Funding & Sponsors
Funding source category [1]
287332
0
University
Query!
Name [1]
287332
0
University of Otago
Query!
Address [1]
287332
0
P.O. Box 4345
Christchurch 8140
New Zealand
Query!
Country [1]
287332
0
New Zealand
Query!
Primary sponsor type
University
Query!
Name
University of Otago
Query!
Address
P.O. Box 4345
Christchurch 8140
New Zealand
Query!
Country
New Zealand
Query!
Secondary sponsor category [1]
286079
0
Hospital
Query!
Name [1]
286079
0
Canterbury District Health Board
Query!
Address [1]
286079
0
P.O. Box 4710
Christchurch 8011
New Zealand
Query!
Country [1]
286079
0
New Zealand
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
289306
0
Southern Health and Disability Ethics Committee
Query!
Ethics committee address [1]
289306
0
1 the Terrace
PO Box 5013
Wellington 6011
Query!
Ethics committee country [1]
289306
0
New Zealand
Query!
Date submitted for ethics approval [1]
289306
0
03/05/2013
Query!
Approval date [1]
289306
0
21/05/2013
Query!
Ethics approval number [1]
289306
0
13/STH/41
Query!
Summary
Brief summary
The primary purpose of the study is to determine whether providing a single high dose of vitamin D using in conjunction with standard treatment (including antibiotics) improves outcomes in adults hospitalised with pneumonia. The main hypothesis is that outcomes will be improved in those taking vitamin D compared to those who are given a placebo.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
40262
0
Prof David Murdoch
Query!
Address
40262
0
Department of Pathology
University of Otago, Christchurch
P.O. Box 4345
Christchurch 8140
Query!
Country
40262
0
New Zealand
Query!
Phone
40262
0
+64 3 364 0590
Query!
Fax
40262
0
Query!
Email
40262
0
[email protected]
Query!
Contact person for public queries
Name
40263
0
Prof David Murdoch
Query!
Address
40263
0
Department of Pathology
University of Otago, Christchurch
P.O. Box 4345
Christchurch 8140
Query!
Country
40263
0
New Zealand
Query!
Phone
40263
0
+64 3 364 0590
Query!
Fax
40263
0
Query!
Email
40263
0
[email protected]
Query!
Contact person for scientific queries
Name
40264
0
Prof David Murdoch
Query!
Address
40264
0
Department of Pathology
University of Otago, Christchurch
P.O. Box 4345
Christchurch 8140
Query!
Country
40264
0
New Zealand
Query!
Phone
40264
0
+64 3 364 0590
Query!
Fax
40264
0
Query!
Email
40264
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
De-identified individual participant data collected during the trial is available.
The data sets have sufficient data for re-analysis and also inclusion in future meta-analyses including all blood/biochemical measurements, chest x-ray findings, and some basic demographic details. However, the data sets have been amended to exclude any data that could lead to participant identification and are de-identified.
Query!
When will data be available (start and end dates)?
Data is immediately available following publication; no end date has been determined
Query!
Available to whom?
Data is available to researchers at reasonable request to Professor Murdoch and at his discretion.
We are required to maintain all records/data for a period of at least 10 years as part of our ethical approval. To protect participant privacy we have opted not to upload data onto a public data base but keep it under the control of Prof Murdoch who at his discretion can provide the data sets to researchers.
Query!
Available for what types of analyses?
Meta analyses
Query!
How or where can data be obtained?
De-identified data sets can be obtained from Prof Murdoch at reasonable request
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF